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300mg is likely to be a cost-saving treatment option compared with sitagliptin 100 
mg when used in combination with other antihyperglycemic agents to treat T2DM.
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IntroductIon: The global clinical and economic burden of type 2 diabetes is 
substantial. New GLP-1 receptor agonists have shown a multifactorial clinical profile 
with the potential to address many of clinical needs. objectIves: The objective 
of this study is to evaluate the cost-effectiveness of once-daily liraglutide vs. once-
weekly exenatide in patients who had failed in metformin, sulfonylurea, or both 
treatments. Methods: A Markov model is made to predict life expectance and 
QALYs of liraglutide and exenatide. Baseline characteristics are consistent with 
DURATION-6 clinical trial. Simulations were run over 35 years (one year as a cycle) 
from a third-party payer perspective. Future costs and benefits are discounted at 
3%. 5 health states were included in the model: “No complications”, “Microvasular 
complications”, “Macrovasular complications”, “both complications” and “Death”. 
Data was extracted from previous studies, head-to-head clinical trial, U.S. con-
sumer Price Index, U.K. Perspective Diabetes Survey, Action in Diabetes and Vascular 
Disease trials, Action to Control Cardiovasular Risk in Diabetes trials and National 
Health Interview Survey data. The transition probabilities in the model vary by the 
age and gender of the patients to simulate the natural progression of type 2 diabe-
tes. results: Liraglutide is associated with improvement of 0.15 QALY. Even though 
it costs more than exenatide, it is still more cost-effective than exenatide. The incre-
mental cost-effectiveness ratios per QALY gained with liraglutide is $138,282 (2013 
US$), which is less than 3 times GDP per capita in 2013. Sensitivity analysis was 
done. Figures in the model were adjusted reasonably, and the results remain robust. 
In other word, liraglutide is more cost-effective than exenatide. conclusIons: 
Long-term projections indicated that liraglutide (injected daily) is more cost-effec-
tive than exenatide (applied weekly).
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objectIves: The IMS CORE Diabetes Model (CDM) is a widely published and previ-
ously validated decision support tool. The model uses the UKPDS 68 risk equations 
(REs) to predict events and has been updated to include the UKPDS 82 REs. The 
objective of this study was to compare cost-effectiveness (CE) results obtained via 
the UKPDS 82 and 68 REs. Methods: Lifetime analyses were conducted using the 
CDM to evaluate the CE of metformin+ sulphonylurea (M+S) compared to metformin 
+ DPP-4 (M+D). Basal insulin rescue therapy (BI) was applied to both arms at HbA1c 
threshold levels of 7.5%. Efficacy data for dual therapy was sourced from a published 
mixed treatment comparison; HbA1c and BMI change of -0.8% and 0.199kg/m2 
(M+D);-0.79% and 0.707kg/m2 (M+S) and -0.82 and 0.545 kg/m2 (BI), respectively, 
were applied. Hypoglycemia rates were estimated based on odds ratios from the 
same systematic review. Results were obtained using for the UKPDS 82 and UKPDS 
68 REs. US 2012 costs were used and discounting was applied at 3.5%. results: 
Quality adjusted life expectancy was 8.157 and 8.038 in patients treated with M+D 
and M+S using UKPDS 68 REs and 7.851 and 7.733 using UKPDS 82 REs. Total direct 
costs were estimated at $77,656 and $66,276 respectively for patients treated with 
M+D and M+S using UKPDS 68 REs and $59,130 and $47,664 respectively using 
UKPDS 82 REs. Incremental differences between REs were less pronounced; incre-
mental costs per quality adjusted life year (QALY) gained were $96,088 and $97,545 
using UKPDS 68 compared to UKPDS 82 REs. conclusIons: The UKPDS risk equa-
tions are widely used in type 2 diabetes cost-effectiveness models. While the new 
equations predict appreciable differences in absolute costs and quality adjusted 
life expectancy the incremental differences were marginal. Consequently health 
economic evaluations using the new UKPDS82 equations appear unlikely to result 
in significantly different results compared with the UKPDS68 REs.
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objectIves: Independent studies have demonstrated that the health utility gain 
associated with the per-event avoidance of non-severe hypoglycaemia episodes 
(NSHE) varies according the baseline rate. Despite this many health technology 
assessments persist in using a mean per-event health disutility. The objective of this 
study was to quantify the bias introduced into an economic evaluation when using 
an average (static) disutility compared to a baseline event rate adjusted (diminish-
ing) disutility. Methods: We compared the one year disutility of daytime NSHE 
for an increasing annual event rate of 1, 5, 10 and 20 events per year. Disutility was 
assessed using a published non-linear approach assuming diminishing marginal 
disutility (D1) and compared to a static approach (S1) assuming a constant utility 
decline of 0.0052 per NSHE. Incremental utility was assessed assuming a compara-
tor intervention associated with (A) 1 NSHE less per year and (B) a 50% reduction in 
NSHE rate. results: The disutilities associated with NSHE event rates of 1, 5, 10 and 
20 events per year were 0.014, 0.024, 0.031 and 0.039 respectively using the marginal 
disutility assumption (D1) and 0.005, 0.026, 0.052 and 0.104 respectively using the 
static approach (S1). Utility gain for 1 NSHE avoided per year was 0.014, 0.002, 0.001 
and 0.001 (D1) and 0.005, 0.005, 0.005 and 0.005 (S1), respectively. Assuming a 50% 
reduction in the rate of NSHE was associated with utility gains of 0.007, 0.005, 0.006 
objectIves: We conducted a cost-effectiveness analysis of two dipeptidyl-pepti-
dase inhibitors, saxagliptin and linagliptin, used in combination with metformin 
for the treatment of Type II diabetes. Methods: A decision tree model was devel-
oped using cost and effectiveness data for saxagliptin + metformin and linagliptin 
+ metformin using published literature. Costs were evaluated using third party 
payer’s perspective and included costs of drugs, physician visits, lab tests, hospital 
costs, and costs associated with adverse events. All costs were adjusted to 2013 
dollars using consumer price index and were calculated for a period of one year. A 
comprehensive literature review of Pubmed, Cochrane library and Google Scholar 
was conducted to obtain data for clinical efficacy and costs. Clinical efficacy values 
were obtained from randomized clinical trials. The primary efficacy measure was 
the proportion of participants achieving HbA1c levels < 7.0%. Base case analysis 
was analyzed as incremental cost per effective treatment. One way sensitivity 
analysis was performed by varying costs by 10% associated with drug treatment 
to evaluate the robustness of the model. results: In the base-case analysis, saxa-
gliptin was found to have better clinical outcomes and lower costs than linagliptin 
as a combination therapy with metformin with an incremental cost effectiveness 
ratio of 30.51. Considering only direct costs for the treatment, expected cost per 
effective treatment for a year was found to be $179.25 for saxagliptin while that 
for linagliptin was $298.99. Sensitivity analysis also indicated saxagliptin to be the 
dominant treatment option. conclusIons: Saxagliptin in our study was found 
to be favored over linagliptin in combination with metformin for the treatment 
of Type II Diabetes. These results may help decision makers develop appropriate 
treatment options. Type II diabetes being a lifestyle disorder, further research 
by inclusion of indirect costs associated with the treatment options may help 
strengthening the results.
PDB76
weighT gain, hyPoglycaemia anD cosT-effecTiveness: whaT Drives 
value among TyPe 2 DiaBeTes TreaTmenTs in The shorT Term
Gordon J.1, Bell K.2, Shah M.2, Ward T.1, McEwan P.1
1HEOR Consulting, Monmouth, UK, 2Bristol-Myers Squibb, New York, NY, USA
objectIves: Current treatment options for managing type 2 diabetes (T2D) have 
significant and varied effects upon patient weight and the incidence of hypogly-
caemia. In the short term, and from the patient’s perspective, the absolute clinical 
effects of therapies are usually observed in the year succeeding therapy initiation. 
Consequently there has been a growing interest among payers and providers to 
understand the influence of weight and hypoglycaemia on the cost-effectiveness 
of T2D treatments. Methods: With this in mind we developed an economic model 
that quantified the quality of life and cost consequences associated with different 
oral treatment strategies over a 1-year time horizon, focusing on the effect of weight 
change and incidence of hypoglycaemia. We illustrate these issues in patients add-
ing dapagliflozin (DAPA) or DPP-4 inhibitors (DPP-4i) to metformin mono-therapy 
(MET). Data describing costs, utilities and absenteeism were sourced from the pub-
lished literature. The model adopts a US societal perspective by including direct 
and indirect costs and benefits and US specific data where possible. results: The 
mean (95% CI) quality adjusted life year (QALY) difference in the DAPA vs. DPP-4i 
comparison (0.02: 0.75 vs. 0.73) was driven by the weight advantage of DAPA with 
no appreciable difference in expected costs ($34: $8,426 vs. $8,392): DAPA was cost-
effective with a cost per-QALY gained estimate of $2,090. conclusIons: In the 
context of this evaluation the driver of economic value over the 1-year period fol-
lowing therapy initiation was weight reduction mediated through quality of life 
gains; whilst a lower incidence of hypoglycaemia was associated with cost offsets in 
medical expenditure and quality of life gains, there was no appreciable difference in 
rates of hypoglycaemia, and hence hypoglycaemia did not drive cost-effectiveness, 
between the two groups.
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objectIves: Short-term cost per outcome analyses focusing on efficient attain-
ment of desired health care outcomes, including quality measures can be useful 
decision-making tools for managed-care payers. Therefore, a simple cost-efficiency 
model was developed to compare the short-term (i.e., 1-year) clinical and economic 
outcomes of treating hyperglycemia with canagliflozin versus sitagliptin in people 
with T2DM. Methods: Data on clinical efficacy and key adverse events (AEs) were 
obtained from a pooled analysis of 2 comparative trials of canagliflozin 300 mg/
day versus sitagliptin100 mg/day. Wholesale drug acquisition costs were used. The 
total and diabetes-related cost savings associated with achieving (vs. not achieving) 
A1C< 7% was specified as $3,055/year and $1,651/year, respectively, based on previ-
ously reported claims database analysis. Savings of $288/year associated with 1% 
decrease in weight, sourced from the literature was applied. AE-related costs (i.e., 
$105-$154/genital mycotic infections and $532/hypoglycemia requiring third-party 
assistance) were derived from treatment algorithms, literature, and reimburse-
ment rates. Total costs, average and incremental costs/key outcomes were calcu-
lated. results: In the simplest analysis evaluating drug cost/outcome only, where 
annual drug-related costs were similar (canagliflozin 300 mg $3,660 vs sitagliptin 
$3,594), the average cost/patient achieving A1C< 7% were lower for canagliflozin 300 
mg compared to sitagliptin ($7,162 vs $8,398/patient per year, respectively). Likewise, 
the average cost per 1% reduction in A1C were lower for canagliflozin 300 mg versus 
sitagliptin ($3,893 vs $5,364). In a comprehensive analysis including medical, drug, 
and adverse event costs, canagliflozin 300 mg dominates sitagliptin in incremental 
cost efficiency in A1C goals. Canagliflozin 300 mg resulted in net savings of $639 per 
patient / year compared to sitagliptin. conclusIons: Based on inputs and assump-
tions used in this model, this 52-week economic analysis suggests that canagliflozin 
